Use of monoclonal antibodies in drug therapy for

Full Text

Abstract

The paper gives the results of international studies of a role of targeted therapy for disseminated colorectal cancer (DCRC). It considers three drugs from this group - cetuximab (erbitux), panitumumab (vectibix), and bevacizumab (avastin). Erbitux demonstrated its activity against DCRC with EGFR receptor hyperexpression and KRAS wide-type and its ability to potentiate the antitumor activity of irinotecan. In DCRC patients without K-RAS mutation, the use of vectibix could significantly increase objective response rates, disease stabilization, and survival to progression as compared with the similar parameters during symptomatic therapy. Avastin therapy leads to a reduction in tumor growth and increases in overall survival (to 25 months) time to disease progression (by 20-25%) as compared to chemotherapy only.

References

  1. Amado R., Wolf M., Peeters M. et al. // J. Clin. Oncol. - 2008. - Vol. 26. - P. 1626-1634.
  2. Avastin Package Insert. - San Francisco: Genentech; 2004 Feb.
  3. Bouganim N., Kavan P., Eid M. et al. // J. Clin. Oncol. - 2009. - Vol. 27 (suppl.). - Abstr. 5027.
  4. Bokemeyer C., Bondarenko I., Hartmann J. T. et al. // J. Clin. Oncol. - 2008. - Vol. 26 (suppl.). - Abstr. 4000.
  5. Cunningham D., Humblet Y. et al. // N. Engl. J. Med. - 2004. - Vol. 351. - P. 337-345.
  6. Damjanov N., Meropol N. J. Oncology. - 2004. - P. 479-503.
  7. Douillard J., Siena S., Cassidy J. et al. // Eur. J. Cancer. - 2009. - Vol. 7, N 3 (suppl.). - Abstr. 10LBA.
  8. Folprecht G. et al. // ASCO GI Symposium. - 2004. - Abstr. 283.
  9. Giantonio B. J., Catalano P. J., Meropol N. J. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 2.
  10. Hochster H. S., Welles L., Hart L. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 3515.
  11. Hurwitz H., Fehrenbacher L., Hainsworth J. et al. // Gastrointestinal Cancers Symposium. - San Francisco, 2004. - P. 182. - Abstr. 286.
  12. Hurwitz H., Fehrenbacher L., Novotny W. et al. // N. Engl. J. Med. - 2004. - Vol. 350. - P. 2335-2342.
  13. Jain R. K. // Nat. Med. - 2001. - Vol. 7. - P. 987-989.
  14. Kabbinavar F. et al. // J. Clin. Oncol. - 2003. - Vol. 21. - P. 60-65.
  15. Lenz H. J., Mayer R. J. et al. // J. Clin. Oncol. - 2005. - Vol. 23 (16s). - Abstr. 3536.
  16. Peeters M., Price T., Hotko Y. et al. // Eur. J. Cancer. - 2009. - Vol. 7, N 3. (suppl.). - Abstr. 14LBA.
  17. Presta L. G. et al. // Cancer Res. - 1997. - Vol. 57. - P. 4593-4599.
  18. Prewett M. et al. // Clin. Cancer Res. - 2002. - Vol. 8. - P. 994-1003.
  19. Rosenberg M. et al. // Symposium ASCO. - 2002. - Abstr. 536.
  20. Rougier P. et al. // J. Clin. Oncol. - 2004. - Vol. 22 (14s). - Abstr. 3513.
  21. Saltz L. B., Cox J. V., Blanke C. et al. // N. Engl. J. Med. - 2000. - Vol. 343. - P. 905-914.
  22. Saltz L., Meropol N. J. et al. // J. Clin. Oncol. - 2004. - Vol. 22. - P. 1201-1208.
  23. Saltz L., Lenz H., Hochster H. et al. // Proc. Am. Soc. Clin. Oncol. - 2005. - Vol. 23. - P. 259s. - Abstr. 3508.
  24. Saltz L., Clarke S., Diaz-Rubio E. et al. // J. Clin. Oncol. - 2007. - Vol. 25 (18s; suppl.). - Abstr. 4028.
  25. Souglakos J., Kalykaki A. et al. // Ann. Oncol. - 2006. - Vol. 17, N 1. - P. 1-6.
  26. Van Cutsem E. et al. // Ann. Oncol. - 2004. - Vol. 15 (suppl. 3). - Abstr. 339P.
  27. Van Cutsem E., Nowacki M. et al. // ASCO. - 2007. - Abstr. 4000.
  28. Van Cutsem E., Peeters M., Siena S. et al. // J. Clin. Oncol. - 2007. - Vol. 25. - P. 1658-1664.
  29. Wein A. et al. // Ann. Oncol. - 2001. - Vol. 12. - P. 1721- 1727.
  30. Wildiers H., Guetens G., De Boeck G. et al. // Br. J. Cancer. - 2003. - Vol. 88. - P. 1979-1986.

Statistics

Views

Abstract: 129

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies